![John Molesphini](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Molesphini
Nessuna posizione attualmente
Profilo
John Molesphini worked as Vice President-Manufacturing Engineering at Arthrocare Corp.
from 2011 to 2018 and as Executive Vice President-Operations at Apollo Endosurgery, Inc. from 2018 to 2023.
He received an undergraduate degree from Rensselaer Polytechnic Institute and an MBA from the University of Michigan.
Precedenti posizioni note di John Molesphini
Società | Posizione | Fine |
---|---|---|
APOLLO ENDOSURGERY, INC. | Direttore operativo | 04/04/2023 |
ARTHROCARE CORPORATION | Corporate Officer/Principal | 01/04/2018 |
Formazione di John Molesphini
Rensselaer Polytechnic Institute | Undergraduate Degree |
University of Michigan | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Arthrocare Corp.
![]() Arthrocare Corp. Medical SpecialtiesHealth Technology ArthroCare Corp. manufactures medical devices for cardiovascular, spinal and other medical treatments. The company was founded on April 29, 1993 and is headquartered in Memphis, TN. | Health Technology |
Apollo Endosurgery, Inc.
![]() Apollo Endosurgery, Inc. Medical SpecialtiesHealth Technology Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX. | Health Technology |
- Borsa valori
- Insiders
- John Molesphini